The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) both recommended the use of Oncotype Dx RS testing in patients with ER + /HER2 − breast cancers [15, 16]. Here, ERBB2 is linked to breast carcinoma.